Tiziana goes stratospheric on plans to develop a MAb for lung damage in COVID-19 patients

11 March 2020
tiziana_large

Shares of UK biotech Tiziana Life Sciences (Nasdaq: AIM: TILS) went ballistic this morning, after the company revealed that it is expediting development of TZLS-501, a novel, fully-human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (MAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2).

Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The company entered into a world-wide license for composition-of-matter of TZLS-501, a fully human MAb targeting IL-6R, with privately-held Swiss biotech Novimmune in 2017.

Tiziana’s shares were up nearly 300% at 126.00 pence mid-morning, having hit 140.00 pence earlier,

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology